Schedule 13G ownership disclosure

UROGEN PHARMA LTD

Ordinary Shares, par value NIS 0.01 per share · CUSIP: M96088105

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Soleus Capital Master Fund, L.P.

    Shares: 2,185,000.00 · Class: 4.7%

  • Soleus Capital, LLC

    Shares: 2,185,000.00 · Class: 4.7%

  • Soleus Capital Group, LLC

    Shares: 2,185,000.00 · Class: 4.7%

  • Soleus Capital Management, L.P.

    Shares: 2,185,000.00 · Class: 4.7%

  • Soleus GP, LLC

    Shares: 2,185,000.00 · Class: 4.7%

  • Guy Levy

    Shares: 2,185,000.00 · Class: 4.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-072156
Form type
SCHEDULE 13G/A
Filer
Soleus Capital Master Fund, L.P.
CIK
CIK 1812275
Filed
Aug 05, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub